VWM
IOVA icon

Vigilare Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

Vigilare Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,975
Closed -$229K – 149
2021
Q4 		$229K Sell
11,975
-9,455
-44% -$208K 0.14% 162
2021
Q3 		$528K Buy
21,430
+271
+1% +$6.38K 0.33% 83
2021
Q2 		$551K Buy
21,159
+10,709
+102% +$278K 0.33% 85
2021
Q1 		$331K Buy
10,450
+4,900
+88% +$203K 0.24% 115
2020
Q4 		$258K Sell
5,550
-1,225
-18% -$48.6K 0.24% 93
2020
Q3 		$223K Sell
6,775
-2,100
-24% -$64.4K 0.23% 106
2020
Q2 		$244K Buy
8,875
+1,775
+25% +$58.4K 0.25% 90
2020
Q1 		$213K Buy
+7,100
New +$188K 0.25% 95

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vigilare Wealth Management's IOVA Position: Q1 2022 in Review

Vigilare Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 11,975 shares — an estimated $229K sold.

Vigilare Wealth Management first reported a position in IOVA in Q1 2020 and held it in 8 quarters. The position peaked at $551K in Q2 2021. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Vigilare Wealth Management reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Vigilare Wealth Management sold 11,975 Iovance Biotherapeutics shares in Q1 2022, an estimated $229K.
  • Vigilare Wealth Management first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 8 quarters.
  • Vigilare Wealth Management's Iovance Biotherapeutics position peaked at $551K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Vigilare Wealth Management's 13F filing for Q1 2022, filed 6 Apr 2022.